ibrexafungerp + dabrafenib

Ibrexafungerp (formerly SCY-078) is a first-in-class, orally bioavailable, semisynthetic triterpenoid antifungal agent that non-competitively inhibits the β-(1,3)-D-glucan synthase enzyme in fungal cell walls. This mechanism disrupts fungal cell wall biosynthesis leading to fungicidal activity against Candida and Aspergillus species, including multi-drug resistant strains such as azole-resistant and echinocandin-resistant isolates. It has demonstrated broad-spectrum antifungal activity with good tissue penetration and a favorable safety profile. Dabrafenib (abbreviated DAB) is a small molecule inhibitor of BRAF kinase used primarily in oncology for treating cancers with BRAF mutations; it is not an antifungal but may be combined experimentally or clinically for specific indications. The combination "SCY-078 + DAB" refers to the use of ibrexafungerp together with dabrafenib. This combination likely represents co-administration of these two agents rather than a fixed-dose combination drug product. Ibrexafungerp was developed by SCYNEXIS for treatment of invasive fungal infections including candidiasis and aspergillosis.

Other names

Ibrexafungerp + Dabrafenib